Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $7.00 Consensus Target Price from Brokerages

Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) have been given a consensus rating of “Moderate Buy” by the seven analysts that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $7.00.

A number of research analysts have recently weighed in on ESPR shares. Wall Street Zen downgraded shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, November 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Esperion Therapeutics in a research report on Wednesday, October 8th. Citigroup restated a “market outperform” rating on shares of Esperion Therapeutics in a research note on Wednesday. HC Wainwright reiterated a “buy” rating and set a $16.00 price target on shares of Esperion Therapeutics in a research note on Friday, September 19th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Esperion Therapeutics in a research note on Wednesday.

Esperion Therapeutics Price Performance

Shares of Esperion Therapeutics stock opened at $2.90 on Friday. The firm has a market cap of $693.28 million, a PE ratio of -5.80 and a beta of 0.92. Esperion Therapeutics has a 1 year low of $0.69 and a 1 year high of $3.94. The stock has a fifty day moving average price of $2.76 and a 200-day moving average price of $1.84.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings results on Thursday, November 6th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.07). The company had revenue of $87.31 million for the quarter, compared to the consensus estimate of $78.33 million. As a group, equities analysts anticipate that Esperion Therapeutics will post -0.29 EPS for the current fiscal year.

Institutional Trading of Esperion Therapeutics

Institutional investors have recently modified their holdings of the business. Vanguard Group Inc. grew its stake in Esperion Therapeutics by 3.2% in the 3rd quarter. Vanguard Group Inc. now owns 12,092,449 shares of the biopharmaceutical company’s stock valued at $32,045,000 after buying an additional 375,620 shares in the last quarter. Two Seas Capital LP grew its position in shares of Esperion Therapeutics by 43.6% in the second quarter. Two Seas Capital LP now owns 9,954,975 shares of the biopharmaceutical company’s stock valued at $9,800,000 after purchasing an additional 3,024,104 shares in the last quarter. Marshall Wace LLP grew its position in shares of Esperion Therapeutics by 46.2% in the second quarter. Marshall Wace LLP now owns 5,312,252 shares of the biopharmaceutical company’s stock valued at $5,206,000 after purchasing an additional 1,679,294 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Esperion Therapeutics by 3.1% during the 2nd quarter. Geode Capital Management LLC now owns 4,583,988 shares of the biopharmaceutical company’s stock valued at $4,513,000 after purchasing an additional 137,691 shares during the period. Finally, Nuveen LLC purchased a new stake in Esperion Therapeutics during the 1st quarter worth about $4,446,000. 47.39% of the stock is currently owned by hedge funds and other institutional investors.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.